Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
Main outcome was the mean visual acuity change at 2 years. DME development was more frequent. One eye in the ranibizumab group vs the PRP group, and the other in the fourth eye.

Related Post